Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. by 源��꽭洹� et al.
Distinct Clinical Features and Outcomes in
Never-Smokers With Nonsmall Cell Lung
Cancer Who Harbor EGFR or KRAS
Mutations or ALK Rearrangement
Hye Ryun Kim, MD1,2; Hyo Sup Shim, MD3; Jin-Haeng Chung, MD4; Young Joo Lee, MD5; Yun Kyoung Hong, MS6;
Sun Young Rha, MD, PhD1,2; Se Hoon Kim, MD7; Sang-Jun Ha, PhD8; Se Kyu Kim, MD2; Kyung Young Chung, MD9;
Ross Soo, MD10; Joo Hang Kim, MD, PhD1,2; and Byoung Chul Cho, MD, PhD1,2
BACKGROUND: The objectives of this study were to determine the proportions of major oncogenic alterations and to
examine survival in genotype-specific subsets of never-smokers with nonsmall cell lung cancer (NSCLC). METHODS:
The authors concurrently analyzed mutations in the epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten
rat sarcoma viral oncogene homolog (KRAS) genes and investigated anaplastic lymphoma kinase (ALK) gene rear-
rangements in samples from 229 never-smokers with NSCLC. ALK rearrangements were identified by fluorescent in
situ hybridization and were confirmed by immunohistochemistry. Mutations in EGFR (exons 18 to 21) and KRAS (co-
dons 12 and 13) were determined by direct sequencing. RESULTS: Of 229 tumors, the frequency of EGFR mutations,
ALK rearrangements, KRAS mutations, and no mutations (wild type [WT]) in any of the 3 genes (WT/WT/WT) was
48%, 8.3%, 3.5%, and 40.2%, respectively. All genetic alterations were mutually exclusive. The median progression-free
survival after treatment with EGFR tyrosine kinase inhibitors (TKIs) was 12.8 months, 6.3 months, 2.1 months, and 1.6
months in patients with EGFR mutations, the WT/WT/WT genotype, KRAS mutations, and ALK rearrangements,
respectively. In a Cox regression model, the adjusted hazard ratio for the risk of disease progression after treatment with
EGFR TKIs was 0.59 (95% confidence interval [CI], 0.40-0.87; P ¼ .008) for patients with EGFR mutations, 4.58 (95% CI,
2.07-10.15; P < .001) for patients with ALK rearrangements, and 4.23 (95% CI, 1.65-10.8; P ¼ .003) for patients with KRAS
mutations. Overall survival also differed significantly among genotypes. CONCLUSIONS: To the authors’ knowledge,
this was the largest comprehensive and concurrent analysis to date of 3 major oncogenic alterations in a cohort of
East Asian never-smokers with NSCLC. Because survival outcomes differed among genotypes, and drugs that target
specific alterations currently are available, genetic profiling to identify genotype-specific subsets can lead to success-
ful treatment with appropriate kinase inhibitors. Cancer 2012;118:729-39. VC 2011 American Cancer Society.
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INTRODUCTION
Lung cancer is a leading cause of cancer mortality worldwide, and the majority of lung cancers are caused by tobacco
smoking.1 However, approximately 25% of lung cancers occur in lifelong never-smokers, and the proportion of never-
smokers with lung cancer has been increasing over time.1-4 The development of lung cancer in never-smokers (LCINS) is
of great concern in East Asian countries, and some estimates suggest that up to 70% of these cancers in women may be
unrelated to tobacco smoking.1,5-7 Currently, LCINS is regarded as a distinct disease entity with a unique tumorigenic
pattern, clinicopathologic features, and natural history.8,9
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LCINS is more likely to be addicted to signaling
from a single oncogene rather than widespread genetic
and epigenetic changes, like those observed in lung can-
cers observed in smokers.10 It is noteworthy that muta-
tions in the epidermal growth factor receptor (EGFR) and
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
(KRAS) genes and anaplastic lymphoma kinase (ALK)
rearrangements are 3 major recurrent oncogenic altera-
tions associated with LCINS.11 EGFR mutations are the
most frequently encountered mutation type in LCINS.
EGFR mutations have been reported in approximately
50% of never-smoker lung cancer patients compared with
10% of smoker lung cancer patients.2,12-14 The high fre-
quency of EGFR mutations in never-smoker patients is
associated with dramatic and durable responses to EGFR
tyrosine kinase inhibitors (TKIs).2,15-20
ALK rearrangement, which results from a small
inversion within chromosome 2p, is a newly identified
driver oncogene in nonsmall cell lung cancer (NSCLC).21-23
Results from a recent clinical trial of crizotinib, an inhibi-
tor of the met proto-oncogene (hepatocyte growth factor
receptor [MET]) and ALK, demonstrated a remarkable
response rate and benefit of progression-free survival in
ALK-positive patients.24 In an unselected NSCLC popu-
lation, the frequency of ALK fusion gene ranged from
1.5% to 7.5%.21-23,25-29 Recently, Shaw et al25 reported a
significantly higher rate (22%) of ALK rearrangements in
never/light smokers with NSCLC, suggesting a strong
association between ALK rearrangements and a never/
light smoking history. However, because most studies,
including that by Shaw et al, investigated predominantly
smokers, the frequency of ALK rearrangements in never-
smokers remains unknown.21,25,29-31
KRAS mutations are oncogenic missense mutations
that occur more frequently in adenocarcinomas from
smokers.32,33 However, a more recent study demonstrated
that KRASmutations are not rare (approximately 15%) in
LCINS; it is noteworthy that KRAS mutations in lung
cancers from never-smokers are more likely to be transi-
tion mutations, unlike those in lung cancers from smok-
ers, which commonly are transversion mutations.34
Because tumors with KRASmutations display primary re-
sistance to EGFR TKIs, molecular evaluation of KRAS is
important to predict clinical treatment outcomes and to
decide on a therapeutic option when treating LCINS.13,35
Recently, the frequencies of mutations in oncogenes
that repeatedly were mutated in lung cancer patients,
including EGFR, KRAS, neuroblastoma RAS viral onco-
gene homolog (NRAS), v-Ha-ras Harvey rat sarcoma viral
oncogene homolog (HRAS), human EGFR 2 (HER2), v-
raf murine sarcoma viral oncogene homolog B1 (BRAF),
ALK, phosphoinositide-3-kinase catalytic alpha polypep-
tide (PIK3CA), tumor protein 53 (TP53), and serine/
threonine kinase 11 (LKB1), were examined in never-
smokers with lung adenocarcinoma.36 It is noteworthy
that, in the study, approximately 90% of 52 tumor sam-
ples harbored well known oncogenic alterations in EGFR,
HER2, ALK, and KRAS: 78.8% of patients had an EGFR
mutation, 5.8% had echinoderm microtubule-associated
protein-like 4 (EML4)-ALK fusion, 3.8% had an HER2
mutation, and 1.9% had a KRASmutation.36 However, it
is unclear whether the results from that study can be gen-
eralized because of the small sample size; furthermore,
treatment responses to chemotherapy or specific kinase
inhibitors were not evaluated.
Herein, we report a comprehensive and concurrent
analysis to date of alterations in 3 major oncogenes associ-
ated with lung cancer in the largest ever cohort of East
Asian never-smokers with NSCLC. We also evaluated
clinicopathologic features and survival outcomes accord-
ing to genotype. This information has clear therapeutic
implications; by identifying clinically relevant molecular
subsets of LCINS, patients potentially can be treated suc-
cessfully with appropriate kinase inhibitors.
MATERIALS AND METHODS
Study Population and Data Collection
Between January 2006 and June 2010, a total of 229 con-
secutive never-smokers with newly diagnosed and histo-
logically confirmed NSCLC for whom genetic data were
available were enrolled at the Yonsei Cancer Center
(Seoul, Korea). Tumor histology was classified according
to World Health Organization criteria.37 Never-smokers
were defined as individuals who had a lifetime smoking
exposure of<100 cigarettes.
Medical records of all patients were reviewed to
extract data on clinicopathologic characteristics. For
patients with metastatic disease, we examined treatment
regimens, the overall response rate (ORR), and survival
outcomes (progression-free survival [PFS] and overall sur-
vival [OS]). Clinical responses were classified using
Response Evaluation Criteria in Solid Tumor (version
1.0).38 PFS was measured from the first day of treatment
to tumor progression or death, and OS was measured
from the date of diagnosis with metastatic disease until
the date of death. In patients with resected NSCLC, recur-
rence-free survival (RFS) was measured from the date of
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surgery for lung cancer until the date of either recurrence
or death, and OS was measured from the date of surgery
until the date of death. Patients were censored on Septem-
ber 31, 2010 if they were alive and progression-free.
Patients without a known date of death were censored at
the time of the last follow-up. This study was approved by
the Institutional Review Board of Severance Hospital. All
patients signed written informed consent for genetic
analysis.
EGFR and KRAS Mutation Analysis
Nucleotide sequencing of the kinase domain of EGFR
(exons 18 to 21) was performed using nested polymerase
chain reaction amplification of the individual exons.39
Details of sequencing have been described previously.
Specific mutations in KRAS exon 2 (codons 12/13) were
identified as described previously.34,35
ALK Rearrangements
To identify ALK rearrangements, fluorescent in situ
hybridization (FISH) studies were performed on forma-
lin-fixed, paraffin-embedded tumors by using a break-
apart probe for ALK (Vysis LSI ALK Dual Color, Break
Apart Rearrangement Probe; Abbott Molecular, Abbot
Park, Ill). A positive FISH result for ALK rearrangement
was defined as>15% of tumor cells with a split signal and
was confirmed by immunohistochemistry. Immunohisto-
chemistry for ALK expression was performed on samples
that were identified as positive for ALK rearrangement in
FISH studies. The formalin-fixed, paraffin-embedded
tumors were sectioned at 4 lm thickness and stained
using a Ventana automated immunostainer (Ventana
Medical Systems, Tucson, Ariz). The antibody against
ALK (mouse monoclonal, clone 5A4; Novocastra, New-
castle, United Kingdom) was diluted 1:30, and sections
were incubated with this diluted antibody for 2 hours at
42C. Signals were detected using an iView detection kit
(Ventana Medical Systems), which is based on a labeled
streptavidin-biotin method.40
Statistical Analysis
Significant differences in variables according to each ge-
notype were tested using the chi-square test, the Fisher
exact test, or t tests, as appropriate. The Kaplan-Meier
method was used to estimate PFS, RFS, and OS, and the
differences according to genotype were compared using
the log-rank test. Adjusted hazard ratios (AHRs) for the
risk of progression or death in response to treatment
according to genotype were calculated using a Cox
regression model that included age, sex, histology, and
performance status as independent variables. All P values
were based on a 2-tailed hypothesis.
RESULTS
Clinicopathologic Characteristics
of Distinct Genotypes
We screened 229 never-smokers with NSCLC for genetic
analysis. This entire cohort included 30 men and 199
women, and the median patient age was 58 years (range,
30-78 years). Histology revealed that 215 patients had ad-
enocarcinoma (93.9%), 7 patients had squamous cell car-
cinoma (3.1%), and 3 patients had large cell carcinoma
(1.3%) (Table 1). On the basis of their genetic mutations,
patients were classified into 4 distinct genotype groups:
EGFR mutations (n ¼ 110; 48%), ALK rearrangements
(n ¼ 19; 8.3%), KRAS mutations (n ¼ 8; 3.5%), and the
wild-type (unmutated) genotype of all 3 genes (WT/WT/
WT) (n ¼ 92; 40.2%) (Fig. 1). Of the 110 EGFR muta-
tions, the majority included deletion mutations in exon
19 (n ¼ 69; 62.7%) and leucine-to-arginine substitution
at codon 858 (L858R) point mutations in exon 21 (n ¼
37; 33.6%). Three patients had double mutations in exon
19 (deletion [del] 2235-2249)/exon 20 (threonine-to-me-
thionine substitution at codon 790 [T790M]), exon 20
(T790M)/exon 21 (L858R), or exon 20 (alanine-to-gly-
cine substitution at codon 871 [A871G])/exon 21
(L858R). In addition, 1 patient had a duplication muta-
tion in exon 20. All KRAS mutation-positive tumors had
transition mutations in codon 12. The frequency of ALK
fusion was 17.1% among patients without EGFR or
KRASmutations.
There were no differences in the baseline characteris-
tics of patients (median age, sex, Eastern Cooperative On-
cology Group performance status, histology, the presence
of central nervous system metastasis, and stage at diagno-
sis) according to genotype (Table 2). Consistent with pre-
vious studies, EGFR mutations, KRAS mutations, and
ALK rearrangements were mutually exclusive. These find-
ings suggested that prospective genotyping for these
genetic mutations may lead to the identification of dis-
tinct and nonoverlapping molecular subsets of lung cancer
patients among never-smokers.
Of 19 ALK rearrangement-positive tumors, 18
(94%) were adenocarcinomas, and 1 was a large cell carci-
noma. Considering the pathologic subtype of adenocarci-
noma according to World Health Organization criteria,37
ALK-positive tumors were significantly more likely to
have abundant signet ring cells than the other pathologic
tumor types (P < .001). When we performed
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immunohistochemistry on the FISH-positive tumors, all
ALK FISH-positive occurrences also were ALK-positive in
immunohistochemical analyses.
Treatment Outcomes of Metastatic NSCLC
According to Genotype
Of 176 patients with metastatic NSCLC, 132 received
EGFR TKI treatment (Table 3). In terms of patient
genotype, 61 of 80 patients (76.2%) who had EGFR
mutations, 8 of 13 patients (61.5%) who had ALK rear-
rangements, 5 of 8 patients (71.4%) who had KRAS
mutations, and 58 of 76 patients (76.3%) who had the
WT/WT/WT genotype received treatment with EGFR
TKIs; the proportion of patients with different genotypes
who were treated with EGFR TKIs was not statistically
significant (Table 3). Most patients received EGFR TKIs
as second-line or third-line treatment (Table 3). None
received other TKIs, including ALK inhibitors. Among 61
patients who had EGFR mutations, 40 patients (65.5%)
had a clinical response to EGFR TKIs, including 14
patients (22.9%) who had stable disease (SD) and 7
patients (11.6%) who had had progressive disease (PD)
after treatment with EGFR TKIs. None of the patients
who had ALK rearrangements (n ¼ 8) and received treat-
ment with EGFR TKIs had a clinical response. One
patient (12.5%) had SD, and the remaining 7 patients
(87.5%) had PD. None of the patients with KRAS muta-
tions (n ¼ 5) had a clinical response to EGFR TKIs. One
of those patients (20%) had SD, and the remaining 4
patients (80%) had PD. In the group with the WT/WT/
WT genotype (n ¼ 58), 6 patients (10.3%) had a partial
response (PR), 36 patients (62.1%) had SD, and 16
patients (27.6%) had PD after receiving treatment with
EGFR TKIs. Patients who had EGFRmutations had a sig-
nificantly higher clinical response rate (65.5%) to EGFR
TKIs than patients who had ALK rearrangements (0%),
Figure 1. This chart illustrates the proportions of major onco-
genic alterations in 229 never-smokers who had nonsmall cell
lung cancer. ALK indicates anaplastic lymphoma kinase;
EGFR, epidermal growth factor receptor; KRAS, v-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog; WT/WT/WT,
wild type (unmutated) of all 3 genes.
Table 1. Baseline Characteristics of Genetically Screened
Never-Smokers With Nonsmall Cell Lung Cancer (N ¼ 229)
Characteristic No. of Patients %
Age, y
Median 58
Range 30-78
Sex
Men 30 13.1
Women 199 86.9
Histology
Adenocarcinoma 215 93.9
SCC 7 3.1
Large cell 3 1.3
NSCLC, NOS 4 1.7
Stagea
I 43 18.8
II 31 13.5
IIIA 41 17.9
IIIB 20 8.7
IV 94 41
Genotype
EGFR 110 48
ALK 19 8.3
KRAS 8 3.5
WT/WT/WTb 92 40.2
Type of mutation
EGFR
Exon19 deletion 69 62.7
Exon 21 L858R 37 33.6
Othersc 4 3.7
KRAS
Gly12Asp (GGTﬁGAT) 5 62.5
Gly12Ser (GGTﬁAGT) 3 37.5
Abbreviations: A, adenine; ALK, anaplastic lymphoma kinase; Asp, aspartic
acid; EGFR, epidermal growth factor receptor; G, guanine; Gly, glycine;
KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; L858R, leu-
cine-to-arginine mutation at codon 858; NOS, not otherwise specified;
NSCLC, nonsmall cell lung cancer; SCC, squamous cell carcinoma; Ser,
serine; T, thymine; WT/WT/WT, wild type for all 3 genes.
a Clinical stage at the time of initial diagnosis was determined according to
the 6th edition of the American Joint Committee on Cancer Cancer Staging
Manual.
b Three patients had double mutations in exon 19 (deletion 2235-2249)/
exon 20 (threonine-to-methionine mutation at codon 790 [T790M]), exon 20
(T790M)/exon 21 (L858R), and exon 20 (alanine-to-glycine mutation at
codon 817 [A871G])/exon 21(L858R). In addition, 1 patient had a duplica-
tion mutation in exon 20.
cWT/WT/WT represents the wild-type EGFR, ALK, and KRAS genes.
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KRAS mutations (0%), or no mutations in these onco-
genes (WT/WT/WT; l10.4%; P< .001).
We also evaluated the ORR to platinum-based
chemotherapy, which was administered as a first-line ther-
apy in the majority of patients. Of 146 patients who
received platinum-based chemotherapy, clinical responses
were observed in 17 patients (25.4%) with EGFR muta-
tions (n ¼ 67), in no patients with ALK rearrangements
(n ¼ 12), in 1 patient (16.7%) with a KRAS mutation (n
¼ 6), and 14 patients (23%) with theWT/WT/WT geno-
type (n ¼ 61) (Table 3). Of the patients who had EGFR
mutations, 39 had SD, and 10 patients had PD. Of the
patients with ALK rearrangements, 9 patients had SD,
and 3 patients had PD (Table 3). There was no significant
difference in the ORR to platinum-based chemotherapy
among the genotypes (P¼ .352).
At the time of this analysis, the median follow-up dura-
tion of patients with metastatic NSCLC was 22.8 months.
Eighty-seven of 176 patients (49.4%) remained alive at the
time of analysis. The 4 genotypes differed significantly in
terms of median PFS after treatment with EGFR TKIs (12.8
months for patients with EGFRmutations vs 6.3 months for
patients with the WT/WT/WT genotype vs 2.1 months for
patients with KRAS mutations vs 1.6 months for patients
with ALK rearrangements) (Fig. 2A). In pair-wise compari-
sons, we observed that patients with EGFR mutations or the
WT/WT/WT genotype had a significantly longer median PFS
than patients with ALK rearrangements or KRAS mutations
(EGFR mutation vs ALK rearrangement, P < .001; EGFR
mutation vs KRAS mutation, P ¼ .002; WT/WT/WT geno-
type vsALK rearrangement,P¼ .001;WT/WT/WT genotype
vsKRASmutation, P¼ .029). Patients with EGFRmutations
tended to have a longer median PFS after treatment with
EGFRTKIs than patients with theWT/WT/WT genotype (P
¼ .093), and the lack of statistical significance may have been
because of the small numbers of patients evaluated.
The median PFS to platinum-based chemotherapy
was not significantly different among the genotypes (7.1
months for patients with EGFR mutations vs 5.9 months
for the WT/WT/WT genotype vs 7.2 months for patients
with KRAS mutations vs 5.0 months for patients with
ALK rearrangements; P ¼ .214) (Fig. 2B). In pair-wise
comparisons, we observed that only patients who had
EGFR mutations had a significantly longer median PFS
Table 2. Clinical Characteristics of Genotype-Specific Subsets of Never-Smokers With Nonsmall Cell Lung Cancer (N ¼ 229)
Genotype: No. of Patients (%) Pa
Characteristic EGFR,
n 5 110
ALK,
n 5 19
KRAS,
n 5 8
WT/WT/WT,
n 5 92
ALK KRAS WT/WT/WT
Age, y .372 .582 .954
Median [range] 57 [33-78] 59 [34-78] 61 [46-73] 59 [30-77]
Sex .641 .246 .758
Men 16 (14.5) 2 (10.5) 0 (0) 12 (13)
Women 94 (85.5) 17 (89.5) 8 (100) 80 (87)
ECOG PS 0-1 110 (1000) 19 (100) 8 (100) 92 (100)
Histology .891b .018b .538b
Adenocarcinoma 105 (95.5) 18 (94.7) 6 (75) 86 (93.5)
SCC 2 (1.8) 0 (0) 0 (0) 5 (5.4)
Large cell 1 (0.9) 1 (5.3) 0 (0) 1 (1.1)
NSCLC, NOS 2 (1.8) 0 (0) 2 (25) 0 (0)
CNS metastasis 9 (8.2) 1 (5.3) 1 (12.5) 7 (7.6)
Stagec .786d .470d .203d
I 24(21.9) 4 (21.1) 2 (25) 13 (14.2)
II 19 (17.3) 3 (15.8) 0 (0) 9 (9.8)
IIIA 19 (17.3) 4 (21.1) 1 (12.5) 19 (20.7)
IIIB 6 (5.5) 1 (5.3) 2 (25) 9 (9.8)
IV 42 (38.2) 7 (36.8) 3 (37.5) 42 (45.7)
Abbreviations: ALK, anaplastic lymphoma kinase; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR,
epidermal growth factor receptor; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NOS, not otherwise specified; NS, nonsignificant; NSCLC,
nonsmall cell lung cancer; SCC, squamous cell carcinoma; WT/WT/WT, wild type for all 3 genes.
a All P values were derived by comparing with EGFR mutant genotype.
b Adenocarcinoma versus all others.
c Clinical stage at the time of initial diagnosis was determined according to the 6th edition of the American Joint Committee on Cancer Cancer Staging
Manual.
d Stages I to IIIA versus stages IIIB/IV.
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compared than patients who had ALK rearrangements (P
¼ .044). In a Cox regression model adjusted for age,
sex, histology, and performance status, the AHR for the
risk of disease progression after EGFR TKI treatment was
0.592 (95% confidence interval [CI], 0.401-0.873; P ¼
.008) for patients with EGFR mutations, 4.583 (95%
CI, 2.070-10.148; P < .001) for patients with ALK rear-
rangements, and 4.225 (95% CI, 1.653-10.801; P ¼
.003) for patients with KRAS mutations (Table 4). These
results indicate that EGFRmutations are a strong, positive
predictive factor for a longer median PFS after EGFR
TKI treatment, whereas ALK rearrangements and KRAS
mutations have a negative predictive impact. No genotype
had a predictive impact on the treatment outcomes in
response to platinum-based chemotherapy.
The median OS differed significantly according to
genotype and 37.2 months for patients with EGFR muta-
tions, 14.3 months for patients with ALK rearrangements,
15.6 months for patients with KRAS mutations, and
33.3 months for patients with the WT/WT/WT genotype
(P¼ .004). In pair-wise comparisons, patients with EGFR
mutations or with theWT/WT/WT genotype had a signif-
icantly longer median OS than patients with ALK rear-
rangements. In addition, patients with EGFR mutations
had a significant longer median OS than patients with
KRAS mutations (EGFR mutations vs ALK rearrange-
ments, P ¼ .001;WT/WT/WT vs ALK rearrangements, P
¼ .016; EGFR mutations vs KRAS mutations, P ¼ .026)
(Fig. 2C). In a Cox regression model adjusted for age, sex,
histology, and performance status, the AHR for the risk of
OS was 0.623 (95% CI, 0.404-0.960; P ¼ .032) for
patients with EGFR mutations, 2.735 (95% CI, 1.329-
5.626; P ¼ .006) for patients with ALK rearrangements,
and 2.208 (95% CI, 0.876-5.564; P ¼ .093) for patients
with KRASmutations (Table 4).
Treatment Outcome of 4 Distinct
Genotypes in Resected NSCLC
In addition, we analyzed RFS in 119 patients with
resected NSCLC who underwent radical surgery. In our
Table 3. Summary of Treatment Outcomes by Genotype in Metastatic Nonsmall Cell Lung Cancer
Genotype: No. of Patients (%) Pa
Variable EGFR,
n 5 80
ALK,
n 5 13
KRAS,
n 5 7
WT/WT/WT,
n 5 76
ALK KRAS WT/WT/WT
Type of treatment
Chemotherapy 67 (83.3) 12 (84.6) 6 (85.7) 61 (80.3) NS .709 .465
EGFR TKI 61 (76.2) 8 (61.5) 5 (71.4) 58 (76.3) .325 NS .316
Line of chemotherapy NS NS NS
First line 67 (100) 12 (100) 6 (100) 61 (100)
Line of EGFR TKI .104 .851 .733
First line 0 (0) 0 (0) 0 (0) 2 (3.4)
Second line 41 (67.2) 8 (100) 3 (60) 40 (69)
Third line 20 (32.8) 0 (0) 2 (40) 16 (27.6)
Best response to chemotherapy
PR 17 (25.4) 0 (0) 1 (16.7) 14 (23)
SD 39 (58.2) 9 (75) 4 (66.7) 33 (54.1)
PD 10 (14.9) 3 (25) 1 (16.7) 14 (23)
Unevaluableb 1 (1.5) 0 (0) 0 (0) 0 (0)
ORR 17 (25.4) 0 (0) 1 (16.7) 14 (23) .060 .635 .837
DCR 56 (83.6) 9 (75) 4 (83.4) 47 (77.1) .437 NS .380
Best response to EGFR TKI
PR 40 (65.5) 0 (0) 0 (0) 6 (10.3)
SD 14 (22.9) 1 (12.5) 1 (20) 36 (62.1)
PD 7 (11.6) 7 (87.5) 4 (80) 16 (27.6)
ORR 40 (65.5) 0 (0) 0 (0) 6 (10.3) .017 .039 <.001
DCR 54 (88.4) 1 (12.5) 1 (20) 41 (72.4) <.001 <.001 .008
Abbreviations: ALK, anaplastic lymphoma kinase; DCR, disease control rate (complete and partial responses plus stable disease); EGFR, epidermal growth
factor receptor; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NS, nonsignificant; ORR, objective response rate; PD, progressive disease; PR,
partial response; SD, stable disease; TKI, tyrosine kinase inhibitor; WT/WT/WT, wild type for all 3 genes.
a All P values were derived from comparisons with the EGFR mutant genotype.
bOne unevaluable patient was lost to follow-up.
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study, no patients received EGFR TKIs as adjuvant treat-
ment. There was no significant difference in the median
RFS among patients according to their genotype (39.7
months for EGFR mutations vs 20.0 months for ALK
rearrangements vs 21.4 months for KRAS mutations vs
26.8 months for WT/WT/WT; P ¼ .344) (Fig. 3A). In a
Cox regression model adjusted for age, sex, histology, per-
formance status, and stage, ALK rearrangements were
associated with a lower OS in patients with resected
NSCLC (AHR, 4.162; 95% CI, 1.529-11.341; P¼ .005)
(Table 5). This suggests that ALK rearrangement may be a
negative prognostic factor for early stage NSCLC. How-
ever, because the ALK rearrangement cohort did not bene-
fit from treatment with EGFR TKIs, it should be noted
that the OS is confounded by postrecurrence treatment.
DISCUSSION
LCINS is a serious problem that should not be ignored,
especially in East Asian countries. Remarkable progress
has been made in identifying the genetic and epigenetic
alterations that define LCINS as a distinct disease en-
tity.41-44 Among many alterations, EGFRmutations, ALK
rearrangements, and KRAS mutations are the 3 most fre-
quently identified and clinically relevant genetic altera-
tions in LCINS.2,12-14,20-23,25-29,34 Genetic profiling of
alterations in these major oncogenes can help identify ge-
notype-specific subsets with the ultimate goal of onco-
gene-specific, targeted treatment.
To our knowledge, this is the most comprehensive
study to date of alterations in the 3 oncogenes associated
with lung cancer in the largest-ever cohort of East Asian
never-smokers with NSCLC. Although previous studies
have examined the clinical features and treatment out-
comes of patients with lung cancer in both never-smokers
and smokers,25 we focused only on LCINS. Other studies
have examined LCINS for multiple mutations, including
EGFR and KRAS mutations, but did not include ALK
rearrangements.41,45 More recently, Sun et al reported
Figure 2. Progression-free survival (PFS) and overall survival
(OS) are illustrated in 4 genotypes of metastatic nonsmall
cell lung cancer (NSCLC): epidermal growth factor receptor
(EGFR), anaplastic lymphoma kinase (ALK), v-Ki-ras2 Kirsten
rat sarcoma viral oncogene homolog (KRAS), and the unmu-
tated wild type (WT) of all 3 genes (WT/WT/WT). (A) PFS is
illustrated in patients who received EGFR tyrosine kinase in-
hibitor (TKI) treatment according to genotype: EGFR (n ¼
61), ALK (n ¼ 8), KRAS (n ¼ 5), and WT/WT/WT (n ¼ 58). (B)
PFS is illustrated in patients who received platinum-based
chemotherapy according to genotype: EGFR (n ¼ 67), ALK (n
¼ 12), KRAS (n ¼ 6), and WT/WT/WT (n ¼ 61). (C) This
Kaplan-Meier survival plot illustrates the OS of patients with
metastatic disease according to genotype: EGFR (n ¼ 80),
ALK (n ¼ 13), KRAS (n ¼ 7), and WT/WT/WT (n ¼ 76).
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multiple genetic alterations in lung adenocarcinoma sam-
ples from never-smokers. However, those authors did not
examine survival outcomes after chemotherapy or EGFR
TKI treatment and only investigated a small patient
cohort.36
The main finding of our study is that genetic profil-
ing of 3 oncogenes enabled the classification of East
Asians with LCINS into 4 distinct genotype groups. Each
genotype was associated with a different response and sur-
vival after treatment with EGFR TKIs: Patients with
EGFRmutations had an approximately 40% reduction in
disease progression or death, whereas patients with ALK
rearrangements or KRAS mutations had significantly
poorer outcomes after treatment with EGFR TKIs.
Therefore, before treating LCINS, we highly recommend
screening for alterations in these 3 oncogenes.
Clear differences in treatment outcomes among ge-
notypes can be predicted by understanding the molecular
basis of the disease. Tumors with EGFR mutations
become reliant on the constitutive activity of the onco-
gene, which is also an excellent target for EGFR TKIs.13
In contrast, patients with ALK rearrangements and KRAS
mutations did not benefit from EGFR TKIs, suggesting
that these genotypes are classified as different subsets of
LCINS. It is noteworthy that patients who had the WT/
WT/WT genotype appeared to benefit from EGFR TKI
treatment, suggesting that WT/WT/WT tumors remain
dependent on an active EGFR pathway for their prolifera-
tion. In a previous study,25 patients with aWT/WT geno-
type for EGFR and ALK, similar to the ALK genotype,
derived no benefit from EGFR TKIs, which was discord-
ant with our result. This discrepancy may be explained by
the finding that direct sequencing may not have sufficient
sensitivity to detect EGFRmutation.44 Another possibility
is that, in that study, both smokers and those with KRAS
mutations were included in WT/WT genotype, which
Table 4. Predictive Impact of Each Gene on Clinical
PFS Outcomes in Patients With Metastatic Nonsmall Cell Lung Cancer
EGFR TKIs Chemotherapy OSa
Genotype No. of
Mutant/WT
AHR
(95% CI)b
P No. of
Mutant/WT
AHR
(95% CI)b
P No. of
Mutant/WT
AHR
(95% CI)b
P
EGFR: Positive vs negative 61/71 0.592 (0.401-0.873) .008 67/79 0.767 (0.536-1.099) .148 80/ 96 0.623 (0.404-0.960) .032
ALK: Positive vs negative 8/124 4.583 (2.070-10.148) < .001 12/134 1.573 (0.815-3.036) .177 13/163 2.735 (1.329-5.626) .006
KRAS: Positive vs negative 5/127 4.225 (1.653-10.801) .003 6/140 0.665 (0.246-1.798) .422 7/169 2.208 (0.876-5.564) .093
Abbreviations: AHR, adjusted hazard ratio; ALK, anaplastic lymphoma kinase; CI, confidence interval; EGFR, epidermal growth factor receptor; KRAS, v-Ki-
ras2 Kirsten rat sarcoma viral oncogene homolog; OS, overall survival; PFS, progression-free survival; TKIs, tyrosine kinase inhibitors; WT, wild type.
aOS survival was measured from the date of the diagnosis of metastatic disease until death.
b Adjusted for age, sex, histology, and performance status.
Figure 3. (A) Recurrence-free survival and (B) overall survival
are illustrated in patients with resected nonsmall cell lung
cancer who underwent lung surgery according to 4 geno-
types: epidermal growth factor receptor (EGFR) (n ¼ 65),
anaplastic lymphoma kinase (ALK) (n ¼ 11), v-Ki-ras2 Kirsten
rat sarcoma viral oncogene homolog (KRAS) (n ¼ 4), and the
unmutated wild type (WT) of all 3 genes WT/WT/WT (n ¼
39).
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could have resulted in poor outcomes after EGFR TKI
treatment. In addition, the higher response rate (10.3%)
to EGFR TKIs among patients with theWT/WT/WT ge-
notype that we observed in our study, compared with the
response rate documented for individuals with this geno-
type (1%) in the Iressa Pan-Asian Study (IPASS), may be
explained by the aforementioned false-negative EGFR
mutation testing in our study or by hidden KRAS muta-
tions or ALK rearrangements in the patients with WT
EGFR in the IPASS trial.20 The ORR (25.4%) for
patients with EGFRmutations to platinum-based chemo-
therapy in our study was lower than that reported in the
IPASS trial (47.3%),20 including large numbers of EGFR
mutations. In addition, the ORR (0%) of ALK-positive
patients in the current study also was lower than what has
been reported previously (25%).25 The small numbers of
patients in our study may account for these discrepancies.
Multiple factors, including line of therapy, number
of therapies, and type of chemotherapy, may have con-
founded the survival outcome. It has been reported
recently that ALK-positive patients may have prolonged
responses to pemetrexed-based chemotherapy.46 There-
fore, it is important to know whether each genotype was
well balanced in terms of the aforementioned confound-
ing factors. In our study, each genotype was well balanced
in terms of the line of therapy and the number of thera-
pies. The proportion of patients exposed to pemetrexed
according to genotype did not differ significantly (13 of
80 patients [16.2%] with EGFR mutations vs 2 of 13
patients [15.3%] with ALK rearrangements vs 1 of 7
patients [14.2%] with KRAS mutations vs 11 of 76
patients [14.4%] with the WT/WT/WT genotype; P ¼
.43). In our study, EGFRmutations accounted for the ma-
jority of LCINS, whereas a few cases were caused either by
ALK fusions or KRAS mutations. Consistent with previ-
ous reports,25,47 mutations in these 3 genes appear to be
mutually exclusive, suggesting that mutations in any 1 of
these major oncogenes is sufficient for tumorigenesis and/
or the maintenance of a malignant phenotype.
The frequency of ALK rearrangements (8.3%) in
our study was similar to that reported for never-smoker
subgroups in previous reports (range, 4.5%-
16.4%).21,23,25,28-31,36,47 However, the frequency of ALK
fusions was 17.1% among patients without EGFR or
KRASmutations, suggesting that this type of genetic alter-
ation is associated with never-smoking status, especially in
patients who are negative for EGFR mutations. After
EGFR mutations, ALK rearrangements are the genetic
alterations that are next most specific for LCINS. Com-
pared with EGFR mutations, which have a significant,
positive correlation with the papillary subtype,41 ALK-
positive tumors are significantly more likely to have abun-
dant signet ring cells, suggesting that these genes may play
a role in transformation. Unlike previous reports
that indicated an association between ALK fusion and
younger age or male gender,14,25,30 we did not observe
such associations in our study. This may be explained in
part by the finding that the vast majority of patients en-
rolled in our study were elderly women. The large propor-
tion of elderly women with ALK rearrangements in our
study also may have confounded the survival outcomes
that we documented for the ALK rearrangement-positive
patients.
Although a previous study reported that KRAS
mutations occur in 15% of Caucasian never-smokers, the
frequency of KRASmutations in Asian populations is con-
sistently lower than this, perhaps reflecting ethnic differ-
ences.34,48 This was confirmed in our study. It is
noteworthy that all KRAS mutations observed in our
study were transitionmutations and were not the transver-
sion mutations more commonly observed in lung cancers
from smokers.
Table 5. Prognostic Impact of Each Gene on Clinical Outcomes of Patients With Resected
Nonsmall Cell Lung Cancer
RFS OSa
Genotype No. of
Mutant/WT
AHR (95%CI)b P AHR (95%CI)b P
EGFR: Positive vs negative 65/54 0.838 (0.501-1.400) .500 0.790 (0.391-1.595) .511
ALK: Positive vs negative 11/108 1.501 (0.587-3.840) .397 4.162 (1.529-11.341) .005
KRAS: Positive vs negative 4/115 1.520 (0.446-5.713) .503 1.074 (0.137-8.406) .946
Abbreviations: AHR, adjusted hazard ratio; ALK, anaplastic lymphoma kinase; CI, confidence interval; EGFR, epidermal
growth factor receptor; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; OS, overall survival; RFS, recur-
rence-free survival; WT, wild type.
aOS was measured from the date of surgery until death.
b Adjusted for age, sex, histology, stage, and performance status.
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The molecularly defined subsets of patients in our
study may benefit from personalized, targeted therapeutic
tools. For example, erlotinib/gefitinib or crizotinib have
been proven markedly efficacious in patients with EGFR
mutations or ALK fusions, respectively. Furthermore,
based on the encouraging results from the Biomarker
Integrated Approached of Targeted Therapy for Lung
Cancer Elimination (BATTLE) trial,49 sorafenib poten-
tially soon may be available to treat lung cancer with
KRAS mutations. According to current data, a significant
proportion of patients with LCINS (approximately 60%)
can be assigned successfully to an effective, targeted
therapy.
We did not elucidate the driver oncogenic muta-
tions or signaling pathways involved in the remaining
40% of LCINS in our study. A variety of genes, such as v-
erb-b2 erythroblastic leukemia viral oncogene (neuroblas-
toma/glioblastoma-derived) homologs 2 through 4
(ERBB2-ERBB4), BRAF, TP53, andMET, may be drivers
of tumorigenesis in LCINS.36,50 Comprehensive, ge-
nome-wide studies are expected to reveal many unidenti-
fied genes that are mutated or rearranged and, thus, are
likely to contribute to the development of LCINS. The
identification and characterization of these unknown par-
ticipants will further our understanding of LCINS and,
ultimately, will lead to improved therapies.
In conclusion, East Asian never-smokers with
NSCLC could be divided into 4 distinct genotype groups
based on genetic profiling of 3 major oncogenes, yielding
a unique and nonoverlapping subset of patients with lung
cancer who have different therapeutic responses and sur-
vival outcomes. Thus, genetic profiling before the initia-
tion of treatment is essential to identify which patients can
benefit from specific targeted therapies and should even-
tually result in personalized therapy options for patients
with LCINS.
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